Syncom Formulations (India) Limited (SYNCOMF) - Total Liabilities
Based on the latest financial reports, Syncom Formulations (India) Limited (SYNCOMF) has total liabilities worth Rs775.88 Million INR (≈ $8.39 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore SYNCOMF shareholders equity momentum to track the company's year-over-year net asset growth rate.
Syncom Formulations (India) Limited - Total Liabilities Trend (2006–2025)
This chart illustrates how Syncom Formulations (India) Limited's total liabilities have evolved over time, based on quarterly financial data. See Syncom Formulations (India) Limited free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Syncom Formulations (India) Limited Competitors by Total Liabilities
The table below lists competitors of Syncom Formulations (India) Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Heidelberg Pharma AG
F:HPHA
|
Germany | €43.94 Million |
|
Vieworks Co. Ltd
KQ:100120
|
Korea | ₩103.22 Billion |
|
OrganiGram Holdings Inc
TO:OGI
|
Canada | CA$149.50 Million |
|
Waterco Ltd
AU:WAT
|
Australia | AU$134.40 Million |
|
Husteel
KO:005010
|
Korea | ₩316.81 Billion |
|
Innate Pharma
NASDAQ:IPHA
|
USA | $84.39 Million |
|
RF Industries Ltd
NASDAQ:RFIL
|
USA | $34.79 Million |
|
Kee Tai Properties Co Ltd
TW:2538
|
Taiwan | NT$12.02 Billion |
Liability Composition Analysis (2006–2025)
This chart breaks down Syncom Formulations (India) Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Syncom Formulations (India) Limited (SYNCOMF) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.68 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.17 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Syncom Formulations (India) Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Syncom Formulations (India) Limited (2006–2025)
The table below shows the annual total liabilities of Syncom Formulations (India) Limited from 2006 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | Rs711.23 Million ≈ $7.69 Million |
-39.39% |
| 2024-03-31 | Rs1.17 Billion ≈ $12.69 Million |
-3.66% |
| 2023-03-31 | Rs1.22 Billion ≈ $13.17 Million |
+41.62% |
| 2022-03-31 | Rs860.17 Million ≈ $9.30 Million |
-17.34% |
| 2021-03-31 | Rs1.04 Billion ≈ $11.25 Million |
+198.41% |
| 2020-03-31 | Rs348.73 Million ≈ $3.77 Million |
-13.57% |
| 2019-03-31 | Rs403.49 Million ≈ $4.36 Million |
-17.70% |
| 2018-03-31 | Rs490.26 Million ≈ $5.30 Million |
-21.96% |
| 2017-03-31 | Rs628.18 Million ≈ $6.79 Million |
-5.83% |
| 2016-03-31 | Rs667.07 Million ≈ $7.21 Million |
+78.45% |
| 2015-03-31 | Rs373.82 Million ≈ $4.04 Million |
-16.63% |
| 2014-03-31 | Rs448.40 Million ≈ $4.85 Million |
+27.51% |
| 2013-03-31 | Rs351.66 Million ≈ $3.80 Million |
+20.70% |
| 2012-03-31 | Rs291.34 Million ≈ $3.15 Million |
-7.24% |
| 2011-03-31 | Rs314.08 Million ≈ $3.40 Million |
-15.73% |
| 2010-03-31 | Rs372.72 Million ≈ $4.03 Million |
+68.09% |
| 2009-03-31 | Rs221.74 Million ≈ $2.40 Million |
-23.40% |
| 2008-03-31 | Rs289.48 Million ≈ $3.13 Million |
+46.94% |
| 2007-03-31 | Rs197.01 Million ≈ $2.13 Million |
+9.15% |
| 2006-03-31 | Rs180.49 Million ≈ $1.95 Million |
-- |
About Syncom Formulations (India) Limited
Syncom Formulations (India) Limited manufactures, markets, and sells pharmaceutical formulation products in India and internationally. It operates through Manufacturing and Dealing in Pharmaceutical Drug and Formulations, Trading of Commodities, and Renting of Properties segments. The company offers antibiotics/antiinfectives, anthelmintics, antimalarial, cardiac, derma, gastro, dry syrups and su… Read more